News
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Shares of Exelixis (NASDAQ: EXEL), a biotech company primarily focused on developing drugs to treat cancer, rallied more than $2 per share during the month of August, according to data from....
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three....
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial....
Why Clovis Oncology Fell 7.1% in August
Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed....
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Shares of Spark Therapeutics Inc. (NASDAQ: ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The company....
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous....
Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market....
Here's Why Novo Nordisk A/S Gained 12% in August
Shares of Danish pharma giant Novo Nordisk A/S (NYSE: NVO) rose 11.7% in August, according to data from S&P Global Market Intelligence. Investors were relieved to see that the sales stall the....
7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020
Image source: Getty Images.Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky -- nearly four-tenths of the way to the moon. That stack would total $1.4....
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
Shares of Incyte (NASDAQ: INCY), a large-cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases, tacked on more than $4 per share, or $850 million....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
I bought my shares of Johnson & Johnson (NYSE: JNJ) and Gilead Sciences, Inc. (NASDAQ: GILD) long ago, when they were trading far lower than they are today. If I had to choose one to keep and....
Here's the Best Dividend Stock in Big Pharma
Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for....
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite....
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The....
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Two of the biggest pharmaceutical companies in the world have been around since the 19th century. Eli Lilly and Company (NYSE: LLY) was founded in 1876, while Pfizer Inc. (NYSE: PFE) began....
3 Stocks That Pay You
Other than the obvious reason that investors like the steady stream of income that comes from investing in dividend-paying stocks, the stability it conveys about a particular business provides a....
3 Dividend Stocks That Thrive in Bear Markets
One of the benefits of dividend investing is the comfort that comes from the regular income stream. But market downturns can many times throw that sense of security out the window. What income....
Why bluebird bio Inc Continued Its March Higher Again Today
Shares of bluebird bio (NASDAQ: BLUE) continued their seemingly unstoppable march higher this week, jumping another 10.8% today as of 2:58 p.m. EDT after two analysts increased their price targets....
Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Found: 3 Stocks Retirees Should Consider Adding
In the hunt for stocks to carry you through your retirement, you're probably looking for low-volatility stocks that supply reliable, steadily rising streams of income. You're past the time....
Why Tiny Organovo Is Giving Money to Huge Biotech Amgen
In the first half of 2017, Amgen (NASDAQ: AMGN) paid out 140 times more in dividends to its shareholders than Organovo Holdings (NASDAQ: ONVO) made in revenue -- during its entire history as a....
Has Gilead Sciences' Big Bounce Begun With the Kite Pharma Buyout?
Once upon a time, Gilead Sciences (NASDAQ: GILD) was one of the hottest biotech stocks on the market. But for most of the last two years, Gilead was anything but hot, with its market cap losing....